{"id":"teprotumumab-n01","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Teprotumumab binds to and blocks the IGF-1 receptor on orbital fibroblasts and immune cells, preventing IGF-1-mediated activation and proliferation that drives the inflammatory and fibrotic processes characteristic of thyroid eye disease (TED). By inhibiting this pathway, it reduces orbital inflammation, decreases hyaluronic acid production, and limits extraocular muscle expansion, thereby improving eye symptoms and disease progression.","oneSentence":"Teprotumumab is a human monoclonal antibody that inhibits insulin-like growth factor-1 receptor (IGF-1R) signaling to reduce inflammation and fibrosis in thyroid eye disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:45.866Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thyroid eye disease (TED) / Graves' ophthalmopathy"}]},"trialDetails":[{"nctId":"NCT07423013","phase":"NA","title":"Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-11-11","conditions":"Thyroid Eye Disease","enrollment":50},{"nctId":"NCT07265258","phase":"PHASE4","title":"A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-12-30","conditions":"Thyroid Eye Disease","enrollment":92},{"nctId":"NCT07113262","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-09-10","conditions":"Thyroid Eye Disease","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Teprotumumab N01","genericName":"Teprotumumab N01","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Teprotumumab is a human monoclonal antibody that inhibits insulin-like growth factor-1 receptor (IGF-1R) signaling to reduce inflammation and fibrosis in thyroid eye disease. Used for Thyroid eye disease (TED) / Graves' ophthalmopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}